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A PHASE II RANDOMIZED OPEN-LABEL STUDY ANTI-CMV HYPERIMMUNE
GLOBULIN VS STANDARD IGIV FOR PREVENTION OF CYTOMEGALOVIRUS
(CMV) REACTIVATION IN HYPOGAMMAGLOBULINEMIC ADULT ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTS (AHSCT)
Bubalo, J.S., Leis, J.F., Curtin, P.T., Simic, A., Subbiah, N.,
Fowler, C., Dunn, A., Grant, B., Maziarz, R.T. Oregon Health and
Science University Hospital, Portland, OR.
Immune globulin is frequently given in the post-transplant phase of
allogeneic HSCT as part of pre-emptive anti-CMV therapy. The goal
of therapy is to reduce the incidence of CMV reactivation and the
subsequent sequelae of CMV disease, to minimize GVHD, and to
limit bacterial infections. Previous IGG replacement strategies pro-
vided scheduled IGIV replacement empirically, without regard for
physiologic hypogammaglobulinemia. The primary aim of this study
was to examine whether anti-CMV hyperimmune globulin (Cyto-
gam®) versus standard IGIV reduced the incidence of CMV activa-
tion in hypogammaglobulinemic patients. Ablative or nonmyeloabla-
tive, CMV, AHSCT patients were monitored biweekly for IGG
levels and received 200 mg/kg QOWof their designated agent if their
IGG was 400 mg/dl during the ﬁrst 120 days after HSCT. Weekly
CMV screening was performed. Antiviral therapy was begun for
evidence of molecular reactivation. A quantitative PCR based assay
was used in the majority of patients and 2 consecutive values 400
copies or 1 value 	400 copies resulted in initiation of antiviral ther-
apy. Ninety patients were enrolled at OHSU between 09/00 and
07/04. Forty-six were randomized to IGIV and 44 to Cytogam®.
Three patients randomized to Cytogam® received 1 dose of IGIV and
4 patients received additional IGIV for therapeutic reasons: ITP(1),
CMV infection (2), parvovirus (1). Groups were demographically
similar for age, gender, and transplant type (URD vs sib). Sixty-two of
90 (69%) patients completed 120 days, 29 (32%) have completed 2
years of follow-up, and 8 are still being actively followed. Forty-two of
90 patients never had an IGG  400 and received no study drug.
Twenty Cytogam® and 28 IVIG patients received study drug by 2
years. Eighteen of 21 patients receiving IVIG and 9/16 patients
receiving Cytogam® had CMV activation in the ﬁrst 120 days (P 
.05) (Table1). There were 2 cases of CMV disease: IGIV-colitis
[survived], Cytogam®-pneumonia [perished]). There were no deaths
attributed to either drug and a single related adverse event was re-
corded, rigors related to the too rapid infusion of Cytogam®. Of the
28 early deaths on this study, 10 were from infections, 3 graft failure,
5 pulmonary, 4 recurrence, 3 GVHD, 1 MOF, and 1 other. In this
small study of hypogammaglobulinemic AHSCT patients, IGG re-
placement with Cytogam® was associated with decreased rates of
CMV activation in the ﬁrst 120 days.
Table 1. Overall Results
Drug/CMV Status
(all patients)
Cytogam R
N  41
IGIV
N  49
No drug/no CMV 10 10
No drug/CMV Activation 11 11
Drug/no CMV 11 8
Drug/CMV activation 9 20
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A SINGLE LOW DOSE OF RASBURICASE FOR TREATMENT OF HYPER-
URICEMIA IN PATIENTS WITH MALIGNANT DISEASES
Triﬁlio, S.M., Gordon, L.I., Tallman,M.S., Evens, A., Singhal, S., Rashid, K.,
Fishman, M., Masino, K., Mehta, J. Northwestern University, Chicago, IL.
Hyperuricemia is a major feature of tumor lysis syndrome (TLS)
in patients with hematololoic malignancies. Because of high tumor
burden or pre-existing renal dysfunction, a conventional approach
with hydration, alkalinization, and allopurinol may not be sufﬁ-
cient to lower uric acid levels rapidly. Rasburicase, a recombinant
urate oxidase enzyme, converts uric acid to soluble allantoin re-
ducing the risk of renal events. The approved dose is 0.15-0.2
mg/kg/d for 3-7 days. The cost is $255/mg corresponding to
approximately $15,000/5day for an average adult. Having had
success with variable lower doses and frequency in a small number
of patients (Triﬁlio et al, ASH 2004), we treated patients with ﬁxed
single doses of the drug with close monitoring of biochemical
parameters. Patients received hydration and allopurinoal as well.
Records of 51 patients treated with single-dose rasburicase were
reviewed with IRB approval. The rasburicase dose used was 3 mg
(n  44), 4.5 mg (n  3), or 6 mg (n  4). The mean baseline uric
acid for the 3 mg group was 10.2 and serum creatinine was 2.9, and
for the combined 4.5/6 mg group, 13 and 2.7. After a single 3 mg
dose, mean uric acid and creatine fell to 5.7 (44% decline) and 2.7
(7% decline) at 24 hours and 4.0 (61% decline) and 2.5 (14%
decline) at 48 hours, respectively. Uric acid levels were in the
normal range (8) in 91% of patients at 24 hours and in all at 48
hours. After a single 4.5/6 mg dose, uric acid and creatinine fell to
8.8 (32% decline) and 2.3 (15% decline) at 24 hours and 4.8 (63%
decline) and 2.2 (19% decline) at 48 hours, respectively. Uric acid
levels were within the normal range at 48 hours in all 7 patients.
Importantly, uric acid levels at 24 hours were within the normal
range in 46 of 47 patients with baseline uric acid 15. All 51
patients, including those with baseline uric acid 	15, achieved
nomral levels within 48 hours. A week after rasburicase, all 51
patients had maintained uric acid levels 8, and had experienced
improvement in creatine to 2.0. No additional renal dysfunction
developed in any patient, and no patient required hemodialysis
(myeloma patients with end-stage renal disease undergoing HSCT
continued hemodialysis). We conclude that a single low dose of
rasburicase is effective in lowering elevated serum uric acid levels
to normal with preservation of renal function. Signiﬁcant cost
savings with this approach (94-97% cost reduction) should reduce
the reluctance to use rasburicase in patients with elevated uric acid
levels.
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RISK FACTORS ASSOCIATED WITH MORTALITY AMONG PERSONS WITH
BREAKTHROUGH ZYGOMYCOSIS AND PRIOR VORICONAZOLE EXPO-
SURE
Triﬁlio, S.M., Bennett, C.L., Yarnold, P.R., Mehta, J., Palella, F.,
Kennedy, L., Parada, J., Blum, W., Kontoyiannis, D. 1. Northwestern
Memorial Hospital, Chicago, IL; 2. Wake Forest University Hospital,
Salem-Winston, NC; 3. Loyola Medical Center, Maywood, IL; 4. Ohio
State University, Columbus, OH; 5. M. D. Anderson Cancer Center,
Houston, TX.
Rates of Zygomycosis have been increasing, predominantly in
patients with hematologic malignancy with or without stem cell
transplant. Proposed factors associated with this change are in-
creasing use of voriconazole for treatment of Aspergillosis. With
the marked increase in the number of cases comes uncertainty of
risk factors for mortality. Investigators from RADAR identiﬁed
factors associated with higher risk of death with voriconazole
associated Zygomycosis. Cases from 13 cancer centers were col-
lected on a standardized case report form, including diagnosis,
species, established risk factors, steroid use, reason for use, con-
comitant infection, surgery, therapy, and outcome. Criteria in-
cluded a minimum of 5 days exposure, clinical diagnosis, and
conﬁrmation with tissue or cytology. Results: 58 patients were
identiﬁed with Zygomycosis and prior voriconazole exposure. Two
thirds had transplants. Overall mortality was 75%. Fifty patients
received voriconazole as prophylaxis. Due to very high mortality
along all categories tested, multivariate analysis identiﬁed only
steroid use and Rhizopus species as signiﬁcant risk factors. A
number of striking observations can be reported. Mortality by
transplant type: related 53% versus unrelated 80%; mortality by
site of infection; lungs  87% versus sinus  58%; mortality by
days of exposure 21days  24% versus 	21 days  77%; mor-
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